Research Article
Serum Adiponectin Level as a Predictor of Subclinical Cushing’s Syndrome in Patients with Adrenal Incidentaloma
Table 3
Demographic, clinical, and metabolic characteristics of the study groups.
| | | SCS group
() | NAI group
() | Control group
() | | | | (%) | (%) | (%) |
| | Gender | | | | | | Female | 5 (62.5) | 19 (59.4) | 22 (73.3) | 0.501 | | Male | 3 (37.5) | 13 (40.6) | 8 (26.7) |
| | | Median () | Median () | Median () | |
| | Age, years | 56.5 (51.5–64) | 61 (56–66) | 32 (24–44) | <0.001 | | Body mass index, kg/m2 | 26.8 (25.0–31.5) | 29.4 (26.4–31.9) | 25.8 (22.8–28.3) | 0.012 | | Waist circumference, cm | 96 (85.5–100.5) | 97.5 (91.5–104.5) | 85 (83–90) | <0.001 | | Waist-to-hip ratio | 0.91 (0.81–0.98) | 0.90 (0.86–0.94) | 0.93 (0.92–0.95) | 0.138 | | Body fat percentage, % | 27.7 (21.5–35.1) | 34.8 (25.8–43.6) | 29.1 (26.0–33.0) | 0.075 | | Fat-free mass, kg | 49.9 (46.3–56.0) | 48.4 (44.5–55.9) | 44.8 (41.1–56.8) | 0.272 | | FBG, mg/dL | 95 (84–121) | 93.5 (88.5–107.5) | 91 (88–97) | 0.338 | | Insulin, μIU/mL | 13.3 (10.0–15.5) | 7.9 (4.5–9.8) | 6.6 (4.8–8.1) | 0.009 | | HOMA-IR | 2.76 (2.07–4.17) | 1.73 (1.01–2.08) | 1.50 (1.20–1.98) | 0.018 | | Total cholesterol, mg/dL | 193.2 (179.6–223.8) | 221 (187.4–251.6) | 173.2 (158.4–187.6) | 0.001 | | LDL-C, mg/dL | 125.0 (108.0–134.5) | 139.0 (101.0–162.0) | 106.5 (94.0–120.0) | 0.014 | | HDL-C, mg/dL | 42.0 (41.5–47.5) | 54.0 (44.0–68.0) | 46.0 (38.0–52.0) | 0.018 | | Triglycerides, mg/dL | 135.5 (103.5–241.0) | 133.0 (102.0–165.0) | 83.50 (66.0–118.0) | 0.002 | | Adiponectin, ng/mL | 12.0 (7.3–12.8) | 24.4 (13.1–48.8) | 39.4 (25.9–44.1) | 0.001 |
|
|
SCS, subclinical Cushing’s syndrome; NAI, nonfunctional adrenal incidentaloma; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
|
